Imugene makes a new appointment to its Scientific Advisory Board

Highlights

• Australia-based Imugene Limited (ASX:IMU) has appointed Dr. Yanghee Woo to its Scientific Advisory Board.
• Woo is a globally recognised surgeon-scientist, who has clinical expertise in robotic surgery and gastric cancer.
• She is expected to enhance the strength of the Company’s already impressive medical and scientific team.

Imugene Limited (ASX:IMU) has made a new addition to its Scientific Advisory Board (SAB). The Company has recently announced the appointment of Dr. Yanghee Woo, MD, FACS, Surgical Oncologist and Associate Professor of Surgery, City of Hope to its SAB.

Do Not Miss: What lies ahead for Imugene Limited (ASX:IMU) in 2022?

Imugene further announced the resignation of its Chief Medical Officer, Dr. Steven Cha, due to some family reasons. He was appointed by the Company early this year to lead its global clinical development efforts and medical affairs. The Company is expected to declare his replacement in due course.

Also Read: Imugene (ASX:IMU) reports publication of CHECKVacc abstract at ASCO 2022

About Dr. Yanghee Woo

Dr. Yanghee Woo is a globally recognised surgeon-scientist, who holds clinical expertise in robotic surgery and gastric cancer. At City of Hope, she holds several key positions, including Vice Chair of International Affairs and Director of GI Minimally Invasive Therapies Program. She is also a Visiting Professor at China-based Xiangya Medical School.

Along with her clinical and teaching experience, she is currently researching gastric cancer inception and viral oncolytic therapy based on the CF33-platform. Moreover, Dr. Woo is part of the team that created CF33-hNIS-antiPDL1 (a chimeric orthopoxvirus), which has shown strong potential in targeting solid tumours and the most popular type of pancreatic cancer, pancreatic ductal adenocarcinoma.

Dr. Woo’s past experience

Prior to commencing her role at the Department of Surgery at City of Hope in 2015, Dr. Woo held different positions at Columbia University Medical Center’s (CUMU) Pancreas Center. Here, she served as Assistant Professor of Surgery and later worked as the Director of Center for Global Excellence in Gastric Cancer Care.

In terms of education, Dr. Woo received her Medical Doctorate from Drexel University Medical School. She completed the Health Careers Program at Harvard University, a research fellowship at Memorial Sloan Kettering Cancer Center, a general surgery residency at CUMC, and a clinical fellowship at Severance Hospital, Yonsei University, Seoul.

As of 10:25 AM AEST, Imugene shares are trading at A$0.195.